Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab
• Serum cytokines and growth factors were assessed during nivolumab treatment. • Follistatin and IP-10 levels are associated with durable clinical benefit. • Levels of serum RANTES are associated with irAE onset. • Clinical benefit and irAEs are regulated by different immune mechanisms.
Gespeichert in:
| Autor*in: |
Oyanagi, Jun [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2019 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
7 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation - Garrote, Pedro J. ELSEVIER, 2019, journal of the International Association for the Study of Lung Cancer, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:132 ; year:2019 ; pages:107-113 ; extent:7 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.lungcan.2019.03.020 |
|---|
| Katalog-ID: |
ELV046737596 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV046737596 | ||
| 003 | DE-627 | ||
| 005 | 20230624124957.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191021s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lungcan.2019.03.020 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000619.pica |
| 035 | |a (DE-627)ELV046737596 | ||
| 035 | |a (ELSEVIER)S0169-5002(19)30376-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Oyanagi, Jun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab |
| 264 | 1 | |c 2019 | |
| 300 | |a 7 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • Serum cytokines and growth factors were assessed during nivolumab treatment. • Follistatin and IP-10 levels are associated with durable clinical benefit. • Levels of serum RANTES are associated with irAE onset. • Clinical benefit and irAEs are regulated by different immune mechanisms. | ||
| 650 | 7 | |a Preclinical and translational research |2 Elsevier | |
| 700 | 1 | |a Koh, Yasuhiro |4 oth | |
| 700 | 1 | |a Sato, Koichi |4 oth | |
| 700 | 1 | |a Mori, Keita |4 oth | |
| 700 | 1 | |a Teraoka, Shunsuke |4 oth | |
| 700 | 1 | |a Akamatsu, Hiroaki |4 oth | |
| 700 | 1 | |a Kanai, Kuninobu |4 oth | |
| 700 | 1 | |a Hayata, Atsushi |4 oth | |
| 700 | 1 | |a Tokudome, Nahomi |4 oth | |
| 700 | 1 | |a Akamatsu, Keiichiro |4 oth | |
| 700 | 1 | |a Nakanishi, Masanori |4 oth | |
| 700 | 1 | |a Ueda, Hiroki |4 oth | |
| 700 | 1 | |a Yamamoto, Nobuyuki |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Garrote, Pedro J. ELSEVIER |t Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation |d 2019 |d journal of the International Association for the Study of Lung Cancer |g Amsterdam [u.a.] |w (DE-627)ELV002331438 |
| 773 | 1 | 8 | |g volume:132 |g year:2019 |g pages:107-113 |g extent:7 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.lungcan.2019.03.020 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 951 | |a AR | ||
| 952 | |d 132 |j 2019 |h 107-113 |g 7 | ||
| author_variant |
j o jo |
|---|---|
| matchkey_str |
oyanagijunkohyasuhirosatokoichimorikeita:2019----:rdcieauosrmrtilvliptetwtavnennmlclln |
| hierarchy_sort_str |
2019 |
| publishDate |
2019 |
| allfields |
10.1016/j.lungcan.2019.03.020 doi GBV00000000000619.pica (DE-627)ELV046737596 (ELSEVIER)S0169-5002(19)30376-9 DE-627 ger DE-627 rakwb eng Oyanagi, Jun verfasserin aut Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab 2019 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Serum cytokines and growth factors were assessed during nivolumab treatment. • Follistatin and IP-10 levels are associated with durable clinical benefit. • Levels of serum RANTES are associated with irAE onset. • Clinical benefit and irAEs are regulated by different immune mechanisms. Preclinical and translational research Elsevier Koh, Yasuhiro oth Sato, Koichi oth Mori, Keita oth Teraoka, Shunsuke oth Akamatsu, Hiroaki oth Kanai, Kuninobu oth Hayata, Atsushi oth Tokudome, Nahomi oth Akamatsu, Keiichiro oth Nakanishi, Masanori oth Ueda, Hiroki oth Yamamoto, Nobuyuki oth Enthalten in Elsevier Garrote, Pedro J. ELSEVIER Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation 2019 journal of the International Association for the Study of Lung Cancer Amsterdam [u.a.] (DE-627)ELV002331438 volume:132 year:2019 pages:107-113 extent:7 https://doi.org/10.1016/j.lungcan.2019.03.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 132 2019 107-113 7 |
| spelling |
10.1016/j.lungcan.2019.03.020 doi GBV00000000000619.pica (DE-627)ELV046737596 (ELSEVIER)S0169-5002(19)30376-9 DE-627 ger DE-627 rakwb eng Oyanagi, Jun verfasserin aut Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab 2019 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Serum cytokines and growth factors were assessed during nivolumab treatment. • Follistatin and IP-10 levels are associated with durable clinical benefit. • Levels of serum RANTES are associated with irAE onset. • Clinical benefit and irAEs are regulated by different immune mechanisms. Preclinical and translational research Elsevier Koh, Yasuhiro oth Sato, Koichi oth Mori, Keita oth Teraoka, Shunsuke oth Akamatsu, Hiroaki oth Kanai, Kuninobu oth Hayata, Atsushi oth Tokudome, Nahomi oth Akamatsu, Keiichiro oth Nakanishi, Masanori oth Ueda, Hiroki oth Yamamoto, Nobuyuki oth Enthalten in Elsevier Garrote, Pedro J. ELSEVIER Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation 2019 journal of the International Association for the Study of Lung Cancer Amsterdam [u.a.] (DE-627)ELV002331438 volume:132 year:2019 pages:107-113 extent:7 https://doi.org/10.1016/j.lungcan.2019.03.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 132 2019 107-113 7 |
| allfields_unstemmed |
10.1016/j.lungcan.2019.03.020 doi GBV00000000000619.pica (DE-627)ELV046737596 (ELSEVIER)S0169-5002(19)30376-9 DE-627 ger DE-627 rakwb eng Oyanagi, Jun verfasserin aut Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab 2019 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Serum cytokines and growth factors were assessed during nivolumab treatment. • Follistatin and IP-10 levels are associated with durable clinical benefit. • Levels of serum RANTES are associated with irAE onset. • Clinical benefit and irAEs are regulated by different immune mechanisms. Preclinical and translational research Elsevier Koh, Yasuhiro oth Sato, Koichi oth Mori, Keita oth Teraoka, Shunsuke oth Akamatsu, Hiroaki oth Kanai, Kuninobu oth Hayata, Atsushi oth Tokudome, Nahomi oth Akamatsu, Keiichiro oth Nakanishi, Masanori oth Ueda, Hiroki oth Yamamoto, Nobuyuki oth Enthalten in Elsevier Garrote, Pedro J. ELSEVIER Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation 2019 journal of the International Association for the Study of Lung Cancer Amsterdam [u.a.] (DE-627)ELV002331438 volume:132 year:2019 pages:107-113 extent:7 https://doi.org/10.1016/j.lungcan.2019.03.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 132 2019 107-113 7 |
| allfieldsGer |
10.1016/j.lungcan.2019.03.020 doi GBV00000000000619.pica (DE-627)ELV046737596 (ELSEVIER)S0169-5002(19)30376-9 DE-627 ger DE-627 rakwb eng Oyanagi, Jun verfasserin aut Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab 2019 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Serum cytokines and growth factors were assessed during nivolumab treatment. • Follistatin and IP-10 levels are associated with durable clinical benefit. • Levels of serum RANTES are associated with irAE onset. • Clinical benefit and irAEs are regulated by different immune mechanisms. Preclinical and translational research Elsevier Koh, Yasuhiro oth Sato, Koichi oth Mori, Keita oth Teraoka, Shunsuke oth Akamatsu, Hiroaki oth Kanai, Kuninobu oth Hayata, Atsushi oth Tokudome, Nahomi oth Akamatsu, Keiichiro oth Nakanishi, Masanori oth Ueda, Hiroki oth Yamamoto, Nobuyuki oth Enthalten in Elsevier Garrote, Pedro J. ELSEVIER Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation 2019 journal of the International Association for the Study of Lung Cancer Amsterdam [u.a.] (DE-627)ELV002331438 volume:132 year:2019 pages:107-113 extent:7 https://doi.org/10.1016/j.lungcan.2019.03.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 132 2019 107-113 7 |
| allfieldsSound |
10.1016/j.lungcan.2019.03.020 doi GBV00000000000619.pica (DE-627)ELV046737596 (ELSEVIER)S0169-5002(19)30376-9 DE-627 ger DE-627 rakwb eng Oyanagi, Jun verfasserin aut Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab 2019 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Serum cytokines and growth factors were assessed during nivolumab treatment. • Follistatin and IP-10 levels are associated with durable clinical benefit. • Levels of serum RANTES are associated with irAE onset. • Clinical benefit and irAEs are regulated by different immune mechanisms. Preclinical and translational research Elsevier Koh, Yasuhiro oth Sato, Koichi oth Mori, Keita oth Teraoka, Shunsuke oth Akamatsu, Hiroaki oth Kanai, Kuninobu oth Hayata, Atsushi oth Tokudome, Nahomi oth Akamatsu, Keiichiro oth Nakanishi, Masanori oth Ueda, Hiroki oth Yamamoto, Nobuyuki oth Enthalten in Elsevier Garrote, Pedro J. ELSEVIER Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation 2019 journal of the International Association for the Study of Lung Cancer Amsterdam [u.a.] (DE-627)ELV002331438 volume:132 year:2019 pages:107-113 extent:7 https://doi.org/10.1016/j.lungcan.2019.03.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 132 2019 107-113 7 |
| language |
English |
| source |
Enthalten in Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation Amsterdam [u.a.] volume:132 year:2019 pages:107-113 extent:7 |
| sourceStr |
Enthalten in Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation Amsterdam [u.a.] volume:132 year:2019 pages:107-113 extent:7 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Preclinical and translational research |
| isfreeaccess_bool |
false |
| container_title |
Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation |
| authorswithroles_txt_mv |
Oyanagi, Jun @@aut@@ Koh, Yasuhiro @@oth@@ Sato, Koichi @@oth@@ Mori, Keita @@oth@@ Teraoka, Shunsuke @@oth@@ Akamatsu, Hiroaki @@oth@@ Kanai, Kuninobu @@oth@@ Hayata, Atsushi @@oth@@ Tokudome, Nahomi @@oth@@ Akamatsu, Keiichiro @@oth@@ Nakanishi, Masanori @@oth@@ Ueda, Hiroki @@oth@@ Yamamoto, Nobuyuki @@oth@@ |
| publishDateDaySort_date |
2019-01-01T00:00:00Z |
| hierarchy_top_id |
ELV002331438 |
| id |
ELV046737596 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV046737596</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624124957.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191021s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.lungcan.2019.03.020</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000619.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV046737596</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0169-5002(19)30376-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Oyanagi, Jun</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Serum cytokines and growth factors were assessed during nivolumab treatment. • Follistatin and IP-10 levels are associated with durable clinical benefit. • Levels of serum RANTES are associated with irAE onset. • Clinical benefit and irAEs are regulated by different immune mechanisms.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Preclinical and translational research</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Koh, Yasuhiro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sato, Koichi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mori, Keita</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Teraoka, Shunsuke</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Akamatsu, Hiroaki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kanai, Kuninobu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hayata, Atsushi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tokudome, Nahomi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Akamatsu, Keiichiro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nakanishi, Masanori</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ueda, Hiroki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yamamoto, Nobuyuki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Garrote, Pedro J. ELSEVIER</subfield><subfield code="t">Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation</subfield><subfield code="d">2019</subfield><subfield code="d">journal of the International Association for the Study of Lung Cancer</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV002331438</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:132</subfield><subfield code="g">year:2019</subfield><subfield code="g">pages:107-113</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.lungcan.2019.03.020</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">132</subfield><subfield code="j">2019</subfield><subfield code="h">107-113</subfield><subfield code="g">7</subfield></datafield></record></collection>
|
| author |
Oyanagi, Jun |
| spellingShingle |
Oyanagi, Jun Elsevier Preclinical and translational research Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab |
| authorStr |
Oyanagi, Jun |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV002331438 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab Preclinical and translational research Elsevier |
| topic |
Elsevier Preclinical and translational research |
| topic_unstemmed |
Elsevier Preclinical and translational research |
| topic_browse |
Elsevier Preclinical and translational research |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
y k yk k s ks k m km s t st h a ha k k kk a h ah n t nt k a ka m n mn h u hu n y ny |
| hierarchy_parent_title |
Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation |
| hierarchy_parent_id |
ELV002331438 |
| hierarchy_top_title |
Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV002331438 |
| title |
Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab |
| ctrlnum |
(DE-627)ELV046737596 (ELSEVIER)S0169-5002(19)30376-9 |
| title_full |
Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab |
| author_sort |
Oyanagi, Jun |
| journal |
Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation |
| journalStr |
Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2019 |
| contenttype_str_mv |
zzz |
| container_start_page |
107 |
| author_browse |
Oyanagi, Jun |
| container_volume |
132 |
| physical |
7 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Oyanagi, Jun |
| doi_str_mv |
10.1016/j.lungcan.2019.03.020 |
| title_sort |
predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab |
| title_auth |
Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab |
| abstract |
• Serum cytokines and growth factors were assessed during nivolumab treatment. • Follistatin and IP-10 levels are associated with durable clinical benefit. • Levels of serum RANTES are associated with irAE onset. • Clinical benefit and irAEs are regulated by different immune mechanisms. |
| abstractGer |
• Serum cytokines and growth factors were assessed during nivolumab treatment. • Follistatin and IP-10 levels are associated with durable clinical benefit. • Levels of serum RANTES are associated with irAE onset. • Clinical benefit and irAEs are regulated by different immune mechanisms. |
| abstract_unstemmed |
• Serum cytokines and growth factors were assessed during nivolumab treatment. • Follistatin and IP-10 levels are associated with durable clinical benefit. • Levels of serum RANTES are associated with irAE onset. • Clinical benefit and irAEs are regulated by different immune mechanisms. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| title_short |
Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab |
| url |
https://doi.org/10.1016/j.lungcan.2019.03.020 |
| remote_bool |
true |
| author2 |
Koh, Yasuhiro Sato, Koichi Mori, Keita Teraoka, Shunsuke Akamatsu, Hiroaki Kanai, Kuninobu Hayata, Atsushi Tokudome, Nahomi Akamatsu, Keiichiro Nakanishi, Masanori Ueda, Hiroki Yamamoto, Nobuyuki |
| author2Str |
Koh, Yasuhiro Sato, Koichi Mori, Keita Teraoka, Shunsuke Akamatsu, Hiroaki Kanai, Kuninobu Hayata, Atsushi Tokudome, Nahomi Akamatsu, Keiichiro Nakanishi, Masanori Ueda, Hiroki Yamamoto, Nobuyuki |
| ppnlink |
ELV002331438 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.lungcan.2019.03.020 |
| up_date |
2024-07-06T21:01:11.858Z |
| _version_ |
1803864948719222784 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV046737596</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624124957.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191021s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.lungcan.2019.03.020</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000619.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV046737596</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0169-5002(19)30376-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Oyanagi, Jun</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Serum cytokines and growth factors were assessed during nivolumab treatment. • Follistatin and IP-10 levels are associated with durable clinical benefit. • Levels of serum RANTES are associated with irAE onset. • Clinical benefit and irAEs are regulated by different immune mechanisms.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Preclinical and translational research</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Koh, Yasuhiro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sato, Koichi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mori, Keita</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Teraoka, Shunsuke</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Akamatsu, Hiroaki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kanai, Kuninobu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hayata, Atsushi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tokudome, Nahomi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Akamatsu, Keiichiro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nakanishi, Masanori</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ueda, Hiroki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yamamoto, Nobuyuki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Garrote, Pedro J. ELSEVIER</subfield><subfield code="t">Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation</subfield><subfield code="d">2019</subfield><subfield code="d">journal of the International Association for the Study of Lung Cancer</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV002331438</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:132</subfield><subfield code="g">year:2019</subfield><subfield code="g">pages:107-113</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.lungcan.2019.03.020</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">132</subfield><subfield code="j">2019</subfield><subfield code="h">107-113</subfield><subfield code="g">7</subfield></datafield></record></collection>
|
| score |
7.40178 |